5 Oral selective tyrosine kinase 2 (TYK2) inhibition with BMS-986165 in patients with systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study (PAISLEY)Shalabh Singhal, Joan T. Merrill, Subhashis Banerjee et al.|Abstracts|2019Cited by 3
Plain Language Summary of the PAISLEY study: deucravacitinib as a treatment for people with systemic lupus erythematosusEric F. Morand, Shalabh Singhal, Nikolay Delev et al.|Expert Opinion on Investigational Drugs|2024Cited by 3
Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: Results from a phase 2, randomized, double-blind, placebo-controlled studyVictoria P. Werth, Shalabh Singhal, Marilyn C. Pike et al.|SKIN The Journal of Cutaneous Medicine|2023Cited by 1